Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia Ling, John Allen, Aleksandra Nikolić et al.|Haematologica|2011Cited by 129
An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myelomaRavi Vij, Susie Jun, Noemi Horvath et al.|American Journal of Hematology|2009Cited by 97